Table 2 Parameter used in the case base
Type of parameter | Base Case value | Range for one-way sensitivity analyses | Reference |
|---|---|---|---|
Demographics | |||
Population | 2,327,222 | [7] | |
Annual population growth | 0.8% | [7] | |
Pediatric weight | 6.7 kg, | ||
Epidemiology | |||
Bronchiolitis incidence | 6.1% | 4–8% | [8] |
% bronchiolitis requiring mechanical ventilation | 7.1% | 2–10% | |
Cost | |||
Survanta® (unit 25 mg), US$ | 13 | 10–15 | [13] |
Curosurf® (unit 240 mg), US$ | 37 | 30–40 | [13] |
Infasurf® (unit 105 mg), US$ | 13 | 10–20 | [13] |
Market Share | |||
Survanta® (unit 25 mg) | 47.3% | 40–57% | [14] |
Curosurf® (unit 240 mg) | 49.2% | 45–55% | [14] |
Infasurf® (unit 105 mg) | 3.4% | 2–6% | [14] |